Divgi C R
Cornell University Medical College, New York, New York, USA.
Oncology (Williston Park). 1996 Jun;10(6):939-53; discussion 954, 957-8.
Monoclonal antibodies (mAbs) of murine origin, when labeled with radionuclides that emit gamma rays, target tumors, permitting detection of disease. Satumomab pendetide (Oncoscint CR/OV), a murine mAb, was recently approved by the FDA for the single-use detection, when labeled with indium-111, of extrahepatic intra-abdominal metastases from colorectal or ovarian cancer. Other radiolabeled mAbs are being explored for their diagnostic potential. The use of radiolabeled mAbs in the therapy of cancer is still far from routine, because the invariable development of antimouse antibodies following administration precludes repeat use, and because bone marrow toxicity limits the amount that can safely be given once. The development of nonimmunogenic antibody forms that will permit multiple administrations has renewed interest in radiolabeled mAbs. Also, better understanding of antigen heterogeneity and methods to upregulate antigen expression offer promise that radiolabeled mAbs may prove useful in treating established metastatic disease, as well as micrometastatic disease.
源自小鼠的单克隆抗体（mAb），当用发射γ射线的放射性核素标记时，可靶向肿瘤，从而实现疾病检测。鼠源单克隆抗体钐[113m]喷替肽（Oncoscint CR/OV）最近获得美国食品药品监督管理局（FDA）批准，用于单次检测，即用铟-111标记时，检测结直肠癌或卵巢癌的肝外腹腔内转移灶。其他放射性标记的单克隆抗体的诊断潜力也在探索之中。放射性标记的单克隆抗体在癌症治疗中的应用仍远未成为常规方法，这是因为给药后抗鼠抗体不可避免地产生，使得无法重复使用，还因为骨髓毒性限制了一次安全给药的剂量。开发允许多次给药的非免疫原性抗体形式，重新引发了人们对放射性标记单克隆抗体的兴趣。此外，对抗原异质性的更好理解以及上调抗原表达的方法，让人们看到放射性标记单克隆抗体可能在治疗已形成的转移性疾病以及微转移性疾病方面发挥作用的希望。
